Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Lower Risk of VTE with Statins & LDL-C Reduction

Atherosclerosis; ePub 2018 Mar 1; Zaccardi, et al

The reduction of venous thromboembolism (VTE) is only partially related to low-density lipoprotein cholesterol (LDL-C) reduction while the benefit was larger than that observed for atherothrombotic risk, a recent study found. The meta-analysis of randomized controlled trials with statin treatment compared a statin with either placebo or another statin treatment and included ≥100 adult participants while lasting at least 24 weeks. Researchers found:

  • 30 RTCs and 159,058 participants (1,431 events) were included, with 28 reporting LDL-C data.
  • Network meta-analysis indicated a larger benefit for rosuvastatin compared to placebo and other statins.
  • The risk reduction in VTE was proportional to LDL-C decrease (37% relative lower risk per each 1 mmol/L reduction in LDL-C).
  • A reduction of 1 mmol/L in LDL-C translates in 37 fewer VTE events per year in 100,000 people, corresponding to 3,162 prevented episodes per year in those aged 50-59 years.


Zaccardi F, Kunutsor SK, Seidu S, Davies MJ, Khunti K. Is the lower risk of venous thromboembolism with statins related to low-density-lipoprotein reduction? A network meta-analysis and meta-regression of randomised controlled trials. [Published online ahead of print March 1, 2018]. Atherosclerosis. doi:10.1016/j.atherosclerosis.2018.02.035.